Compare Mesoblast Limited (MESO) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Wells Fargo & Co — how do they compare? Mesoblast Limited trades at $16.25 (market cap $2.17B), while Wells Fargo & Co trades at $86.94 (market cap $261.45B). The key difference: Wells Fargo & Co is far larger — about 120.5× Mesoblast Limited's market cap, and Wells Fargo & Co pays a 2.09% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WFC | |
|---|---|---|
Market Cap | $2.17B | $261.45B |
Sector | Technology | Financials |
52-Week High | $20.96 | $96.40 |
52-Week Low | $12.88 | $73.42 |
Enterprise Value | $2.17B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Wells Fargo (WFC) trades at $86.3, down 1.4% on the day, with a bullish technical outlook from moving averages and a consensus analyst price target of $97.36. The bank reported strong Q2 2026 earnings, beating EPS estimates with $1.96 actual versus $1.73 expected, driven by net interest income and fee growth. Revenue trends show steady growth from $83.7B in 2025 to a projected $87.0B in 2026, with net income margins improving to 25.97%. Recent news highlights AI investments in wealth management and a healthy investment banking pipeline.
The outlook for WFC is positive, supported by earnings momentum, dividend payments, and analyst upgrades. Key opportunities include continued revenue growth and efficiency gains post-asset cap removal. Risks involve net interest margin pressure, expense management challenges, and macroeconomic sensitivity. Institutional sentiment is mixed but leans bullish, with 45% of analysts rating it a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
